Exhibition Stands > News

Matrix given first tentative approval on HIV drug

08 Apr 2009

Pharmaceutical firm Mylan has announced its subsidiary Matrix Laboratories has taken the first step towards receiving the green light for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in 200 mg and 300 mg doses.

It has received the first tentative approval from the US Food and Drug Administration (FDA) for the HIV drugs.

The company has a commitment to providing affordable HIV and Aids drugs - an ethos that benefits the 30 per cent of patients in poorer nations that rely on its products.

"This product approval is yet another important step in providing access to a range of critical HIV medications to patients in developing countries," explained Mylan vice chairman and chief executive Robert J Coury.

He added the company will continue its efforts to bring down the cost of viral treatments.

Mylan recently announced it would have the right to market five mg Desloratadine Tablets - the generic version of Schering-Plough''s Clarinex allergy medication - from July 1st 2012.